MAP Pharma (MAPP) Misses Q4 Views by 2c
- Top 10 News for 4/13 - 4/17: China Regulation, Greek Debt Rattle Markets; Netflix Rockets on Results; M&A News, Rumors Abound
- U.S. Antitrust Lawyers May Move to Block Comcast (CMCSA), Time Warner Cable (TWC) Deal
- Teva (TEVA) Said Considering Bid for Mylan (MYL)
- General Electric (GE) Tops Q1 EPS by 1c
- Stock Futures Deep in the Red
MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) reported Q4 loss of $0.46, 2 cents worse than the analyst estimate of ($0.44).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ERBA Diagnostics (ERB) to Delay 10-K Filing; Notes Continued Trouble Completing Financial Statements
- Nord Anglia Education, Inc. (NORD) Misses Q2 EPS by 1c, Maintains FY Guidance
- Reynolds American (RAI) Tops Q1 EPS by 6c
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!